0001193125-26-219365
SEC filingFractyl Health announced Q1 2026 financial results with net income of $9.2 million driven by non-cash warrant liability gains, reduced R&D expenses, and cash runway into early 2027.
Fractyl Health reported first quarter 2026 results reflecting disciplined cost management amid advancing its clinical pipeline. GAAP net income swung to a $9.2 million profit from a $23.7 million loss in the prior year, primarily due to a $30.1 million non-cash favorable change in warrant liability fair value, which management emphasized does not reflect underlying operations. Excluding this, operating expenses declined $3.9 million year-over-year, driven by lower R&D spending of $15.6 million versus $19.4 million, attributed to efficiencies in Revita and Rejuva programs, alongside stable SG&A at $5.2 million. Adjusted EBITDA loss narrowed to negative $18.0 million from negative $23.0 million, underscoring improved core operational performance. Cash position stood at $63.2 million as of March 31, 2026, sufficient to fund operations into early 2027, extending beyond key Revita REMAIN-1 Pivotal Cohort topline data expected in early Q4 2026. CEO Harith Rajagopalan highlighted Revita's potential as a procedural off-ramp for post-GLP-1 weight maintenance, supported by prior positive midpoint cohort data showing 70% less weight regain and dose-dependent effects. Upcoming milestones include Q2 2026 REVEAL-1 1-year data, Q3 2026 REMAIN-1 Midpoint 1-year data, and a potential late Q4 FDA De Novo submission. Rejuva progress includes Netherlands CTA approval for RJVA-001, with first-in-human dosing planned for H2 2026. These updates position Fractyl to deliver pivotal readouts within its funded runway, critical for investors tracking metabolic therapy advancement.